Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

Article Respiratory System

Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial

Manuel Taboada et al.

Summary: High-dose dexamethasone reduces clinical worsening in COVID-19 patients receiving oxygen therapy within 11 days after randomization.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Critical Care Medicine

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

Anders Granholm et al.

Summary: The study showed that in patients with COVID-19 and severe hypoxaemia, daily use of dexamethasone 12 mg compared to 6 mg had high probabilities of benefit and low probabilities of clinically important harm in all outcomes up to 90 days.

INTENSIVE CARE MEDICINE (2022)

Add to Collection

Article Critical Care Medicine

High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A Multicenter, Randomized Open-Label Clinical Trial

Luis Patricio Maskin et al.

Summary: Among patients with ARDS caused by COVID-19, the use of higher doses of dexamethasone compared with the recommended low-dose treatment did not show an increase in ventilator-free days. However, the higher dose significantly improved the time required to liberate them from the ventilator.

JOURNAL OF INTENSIVE CARE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia The COVID STEROID 2 Randomized Trial

Marie W. Munch et al.

Summary: In patients with COVID-19 and severe hypoxemia, the use of 12 mg/d of dexamethasone compared to 6 mg/d did not lead to a statistically significant difference in the number of days alive without life support at 28 days. The study may have lacked the power to detect a significant effect.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Anesthesiology

Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan

Marie Warrer Munch et al.

Summary: The COVID STEROID 2 trial aims to evaluate the benefits and harms of using higher (12 mg) vs. lower (6 mg) doses of dexamethasone in patients with COVID-19. The study plans to recruit 1,000 patients, with the primary outcome being the number of days alive without life support at day 28. This will help determine the optimal dosage of systemic corticosteroids for COVID-19 patients with severe hypoxia.

ACTA ANAESTHESIOLOGICA SCANDINAVICA (2021)

Add to Collection

Review Multidisciplinary Sciences

Impact of Covid-19 on health-related quality of life of patients: A structured review

Ak Narayan Poudel et al.

Summary: The research found that the impact of Covid-19 on the HRQoL of Acute and Long Covid patients is substantial, especially in Acute Covid, females, older ages, patients with more severe disease, and patients from low-income countries.

PLOS ONE (2021)

Add to Collection

Article Economics

The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data

Cathrine Elgaard Jensen et al.

Summary: The study developed the first Danish value set for the EQ-5D-5L based on interviews with a representative sample of the Danish adult population. The chosen hybrid model combining cTTO and DCE data provided consistent results for modelling the final Danish value set.

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2021)

Add to Collection

Article Respiratory System

Long-term outcomes following severe COVID-19 infection: a propensity matched cohort study

Joanne McPeake et al.

Summary: The study found that emotional and social problems are common long-term consequences for survivors of severe COVID-19 infection. Coordinated rehabilitation is essential to ensure optimal recovery for patients.

BMJ OPEN RESPIRATORY RESEARCH (2021)

Add to Collection

Article Anesthesiology

Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trial

Marie Warrer Munch et al.

Summary: The study aimed to assess the effects of low-dose hydrocortisone on patients with severe hypoxia due to COVID-19, but was terminated early with only 3% of the planned sample size enrolled, leading to imprecise estimates of benefits and harms.

ACTA ANAESTHESIOLOGICA SCANDINAVICA (2021)

Add to Collection

Review Health Care Sciences & Services

A structured methodology review showed analyses of functional outcomes are frequently limited to survivors only in trials enrolling patients at high risk of death

Elizabeth Colantuoni et al.

Summary: This structured methodology review assessed statistical approaches used in randomized controlled trials with patients at high risk of death and provided recommendations for reporting future RCTs. The study found that statistical analyses of functional outcomes in these trials are often conducted only among survivors, potentially leading to misleading conclusions. Standards for reporting should be established due to the increasing number of RCTs conducted among patients hospitalized with COVID-19 and other critical illnesses.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)

Add to Collection

Article Economics